Background: There have been reports on the use of erlotinib in non-small cell lung cancer
(NSCLC) patients after gefitinib resistance occurs, and it has been stated that erlotinib may …

Inhibition of epidermal growth factor receptor (EGFR) has become an important target in the
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …

Background: Non-small cell lung cancer (NSCLC) has a poor prognosis despite
conventional treatments of surgery, radiotherapy, and chemotherapy. Small-molecule …

7022 Background: In phase II studies, erlotinib has shown single agent activity in a number
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …

Aims and background: Erlotinib approval was supported by the positive results of a large
multicentric phase III trial (BR. 21 study) that included 10% Asiatic patients and the …

7160 Background: The HER1/EGFR inhibitor erlotinib significantly prolongs survival of
patients with previously-treated advanced NSCLC. Methods for selecting patients most likely …

7010 Background: Oral erlotinib is a potent HER1/EGFR tyrosine kinase-phosphorylation
inhibitor with single-agent antitumor activity and has shown additive effects when added to …

Background The purpose of this study was to evaluate the efficacy of erlotinib as front-line
treatment in clinically selected patients with non–small-cell lung cancer (NSCLC). Patients …

Background The first-generation epidermal growth factor receptor tyrosine kinase inhibitors
gefitinib and erlotinib have both been proven effective for treating advanced non–small cell …

BACKGROUND: Targeting epidermal growth factor receptors (EGFR) is an innovative
approach to managing non-small cell lung cancer (NSCLC) which harbors EGFR mutation …